Vcp Valosin Containing Protein is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
| Valosin-Containing Protein |
|---|
| Gene Symbol | VCP |
| Full Name | Valosin-containing protein |
| Chromosome | 9p13.3 |
| NCBI Gene ID | 7415 |
| OMIM | 601023 |
| Ensembl ID | ENSG00000165288 |
| UniProt ID | P55072 |
| Associated Diseases | Amyotrophic Lateral Sclerosis, Frontotemporal Dementia, Inclusion Body Myopathy |
VCP (Valosin-Containing Protein), also known as p97 or CDC48 in yeast, is a gene on chromosome 9p13.3 encoding a AAA+ ATPase essential for protein quality control, ER-associated degradation (ERAD), and autophagy. VCP mutations cause amyotrophic lateral sclerosis (ALS), frontotemporal dementia (FTD), and inclusion body myopathy with Paget disease of bone (IBMPFD). The protein forms a hexameric ring structure that extracts ubiquitinated proteins from membranes or protein complexes for proteasomal degradation, making it critical for cellular proteostasis.
VCP encodes valosin-containing protein (also known as p97 or CDC48 in yeast), a AAA+ (ATPases Associated with diverse cellular Activities) ATPase essential for protein quality control, ER-associated degradation (ERAD), and autophagy1. VCP/p97 extracts ubiquitinated proteins from membranes or protein complexes for proteasomal degradation. It plays critical roles Functions
- Autophagy: Critical for autophagosome maturation and clearance of protein aggregates
- DNA Repair: Participates in double-strand break repair and replication fork maintenance
- Cell Cycle Regulation: Controls mitotic spindle assembly and cytokinesis
- Mitochondrial Quality Control: Involved in mitophagy and mitochondrial protein turnover
- Nuclear Envelope Reconstruction: Required for nuclear envelope reformation after mitosis
VCP/p97 forms a hexameric ring structure:
- N-terminal Domain: Binds cofactors and substrates
- D1 ATPase Domain: Core ATPase activity
- D2 ATPase Domain: Primary ATPase activity
- C-terminal Domain: Substrate recruitment and regulation
VCP functions with numerous cofactors that determine its substrate specificity:
- UFD1L-NPL4: ERAD substrate recruitment
- p47: Membrane fusion and autophagy
- UBXD1, UBXD2, UBXD8: Various ERAD pathways
- SAKS1: Autophagosome maturation
VCP is widely expressed in all tissues with high expression in brain and muscle:
- Neuronal Expression: High in cortical neurons, motor neurons, and hippocampal neurons
- Subcellular Localization: Cytoplasm, nucleus, and endoplasmic reticulum
- Essential Gene: Knockout is embryonic lethal in mice
In neurons, VCP is particularly important for:
- Proteostasis maintenance
- Synaptic function
- Mitochondrial quality control
VCP mutations cause autosomal dominant ALS/FTD2:
- Inheritance: Autosomal dominant
- Prevalence: ~1-2% of familial ALS
- Key Mutations: R155H, R155P, A232E, A232T, R191Q
- Pathogenesis:
- Impaired autophagy leading to protein aggregate accumulation
- ERAD dysfunction causing ER stress
- TDP-43 pathology (characteristic of ALS)
- Mitochondrial dysfunction
- Disrupted lysosomal function
VCP mutations cause FTD with or without ALS3:
- Clinical Phenotypes: Behavioral variant FTD, progressive aphasia
- Pathology: TDP-43 positive inclusions
- Overlap: Often co-occurs with ALS
¶ Inclusion Body Myopathy (IBM)
VCP mutations cause inclusion body myopathy with early-onset Paget disease of bone (PDB) and FTD (IBMPFD)4:
- Clinical Features: Progressive muscle weakness, bone deformities, dementia
- Pathology: Rimmed vacuoles, TDP-43 inclusions
- Paget Disease of Bone: Bone turnover abnormalities
- Charcot-Marie-Tooth Disease: Rare VCP variants
- Parkinson's Disease: VCP activity affects alpha-synuclein clearance
- ERAD Dysfunction: Reduced clearance of misfolded proteins from ER
- Autophagy Defects: Impaired autophagosome-lysosome fusion
- Aggregate Accumulation: TDP-43 and other proteins accumulate
- ER Stress: Unfolded protein response activation
- Mitochondrial Dysfunction: Reduced mitophagy, energy deficits
- Lysosomal Impairment: Reduced autophagic flux
- Nuclear Envelope Abnormalities: Disrupted nuclear pore function
- High metabolic demands make motor neurons particularly vulnerable
- Long axons require efficient protein turnover
- Impaired axonal transport
- VCP Inhibitors: Target ATPase activity (e.g., DBeQ, ML240)
- Allosteric Modulators: Target cofactor interactions
- Proteasome Enhancers: Enhance overall proteasome function
- Autophagy Inducers: Bypass VCP dysfunction (e.g., rapamycin, trehalose)
- ** chaperone Inducers**: Enhance protein folding capacity
- Wild-type VCP Delivery: AAV-mediated gene therapy
- Allele-specific Editing: CRISPR approaches for specific mutations
- RNAi: Reduce toxic mutant protein expression
-
Johnson JO et al. (2010). "Mutations in VCP cause ALS and FTD." Nature. PMID:20037591. DOI:10.1038/nature08971
-
Watts GD et al. (2010). "VCP inclusion body myopathy and Paget disease." Nat Rev Neurol. PMID:21499257. DOI:10.1038/nrneurol.2010.178
-
Kim NC et al. (2015). "VCP dysfunction in neurodegeneration." Brain. PMID:25807384. DOI:10.1093/brain/awv033
-
Nalbandian A et al. (2015). "VCP disease: clinical and molecular aspects." Mol Genet Metab. PMID:25800554.
-
Buchan JR et al. (2013). "p97/VCP drives muscle degeneration." J Cell Biol. PMID:24297994.
Recent advances in VCP research include:
- Structural Studies: Cryo-EM structures of VCP in complex with cofactors
- iPSC Models: Patient-derived motor neurons showing disease phenotypes
- Therapeutic Screening: Identification of small molecule VCP modulators
- Biomarkers: Development of blood and CSF markers for VCP disease
The study of Vcp Valosin Containing Protein has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
-
- 1 Johnson JO, et al. (2010). Mutations in VCP cause ALS and FTD. Nature. PMID:20037591.
- 2 Watts GD, et al. (2010). VCP inclusion body myopathy and Paget disease. Nat Rev Neurol. PMID:21499257.
- 3 Kim NC, et al. (2015). VCP dysfunction in neurodegeneration. Brain. PMID:25807384.
- 4 Nalbandian A, et al. (2015). VCP disease: clinical and molecular aspects. Mol Genet Metab. PMID:25800554.
- 5 Buchan JR, et al. (2013). p97/VCP drives muscle degeneration. J Cell Biol. PMID:24297994.
- 6 Yao Y, et al. (2019). VCP and autophagy in neurodegeneration. Nat Rev Neurosci. PMID:30602767.
- 7 Tang WK, et al. (2020). Structural insights into VCP function. Nat Struct Mol Biol. PMID:32807928.
-